Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Koshimune, Ryuichiro ^a   Aoe, Motoi ^a   Toyooka, Shinichi ^a   Hara, Fumikata ^a   Ouchida, Mamoru ^a   Tokumo, Masaki ^a   Sano, Yoshifumi ^a   Date, Hiroshi ^a   Shimizu, Nobuyoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DNA FRAGMENT; MEVALONIC ACID; MINODRONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TROPENZILINE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE;

ADENOSQUAMOUS CARCINOMA; AGAR GEL ELECTROPHORESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCULATION; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; CELL CYCLE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; LUNG TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; LUNG NEOPLASMS;

EID: 33846840750     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-8     Document Type: Article

References (32)

1. Jemal A Siegel R Ward E Murray T Xu J Smigal C Thun MJ Cancer statistics, 2006 CA Cancer J Clin 2006 56 2 106-130 16514137
2. Shipman CM Rogers MJ Apperley JF Russell RG Croucher PI Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity Br J Haematol 1997 98 3 665-672 10.1046/ j.1365-2141.1997.2713086.x 9332325
3. Shipman CM Croucher PI Russell RG Helfrich MH Rogers MJ The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway Cancer Res 1998 58 23 5294-5297 9850051
4. Aparicio A Gardner A Tu Y Savage A Berenson J Lichtenstein A In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates Leukemia 1998 12 2 220-229 10.1038/sj.leu.2400892 9519785
5. Derenne S Amiot M Barille S Collette M Robillard N Berthaud P Harousseau JL Bataille R Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment J Bone Miner Res 1999 14 12 2048-2056 10.1359/jbmr.1999.14.12.2048 10620064
6. Tassone P Forciniti S Galea E Morrone G Turco MC Martinelli V Tagliaferri P Venuta S Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines Leukemia 2000 14 5 841-844 10.1038/sj.leu.2401770 10803515
7. Takahashi R Shimazaki C Inaba T Okano A Hatsuse M Okamoto A Hirai H Ashihara E Nakagawa M A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells Leuk Res 2001 25 1 77-83 10.1016/S0145-2126(00)00087-4 11137564
8. Giuliani N Pedrazzoni M Passeri G Girasole G Bisphosphonates inhibit IL-6 production by human osteoblast-like cells Scand J Rheumatol 1998 27 1 38-41 10.1080/030097498441155 9506876
9. Senaratne SG Pirianov G Mansi JL Arnett TR Colston KW Bisphosphonates induce apoptosis in human breast cancer cell lines Br J Cancer 2000 82 8 1459-1468 10780527
10. Lee MV Fong EM Singer FR Guenette RS Bisphosphonate treatment inhibits the growth of prostate cancer cells Cancer Res 2001 61 6 2602-2608 11289137
11. Fromigue O Lagneaux L Body JJ Bisphosphonates induce breast cancer cell death in vitro J Bone Miner Res 2000 15 11 2211-2221 10.1359/ jbmr.2000.15.11.2211 11092402
12. Jagdev SP Coleman RE Shipman CM Rostami HA Croucher PI The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel Br J Cancer 2001 84 8 1126-1134 10.1054/bjoc.2001.1727 11308265
13. Tassone P Tagliaferri P Viscomi C Palmieri C Caraglia M D'Alessandro A Galea E Goel A Abbruzzese A Boland CR Venuta S Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro Br J Cancer 2003 88 12 1971-1978 10.1038/sj.bjc.6600986 12799645
14. Widler L Jaeggi KA Glatt M Muller K Bachmann R Bisping M Born AR Cortesi R Guiglia G Jeker H Klein R Ramseier U Schmid J Schreiber G Seltenmeyer Y Green JR Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa) J Med Chem 2002 45 17 3721-3738 10.1021/jm020819i 12166945
15. Suri S Monkkonen J Taskinen M Pesonen J Blank MA Phipps RJ Rogers MJ Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: A model of bisphosphonate-induced gastrointestinal toxicity Bone 2001 29 4 336-343 10.1016/S8756-3282(01)00589-0 11595616
16. Chen T Berenson J Vescio R Swift R Gilchick A Goodin S LoRusso P Ma P Ravera C Deckert F Schran H Seaman J Skerjanec A Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases J Clin Pharmacol 2002 42 11 1228-1236 10.1177/ 009127002762491316 12412821
17. Sato M Grasser W Endo N Akins R Simmons H Thompson DD Golub E Rodan GA Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure J Clin Invest 1991 88 6 2095-2105 295810 1661297
18. Cui N Nomura T Noma H Yokoo K Takagi R Hashimoto S Okamoto M Sato M Yu G Guo C Shibahala T Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice Clin Cancer Res 2005 11 7 2713-2719 10.1158/1078-0432.CCR-04-1767 15814653
19. Segawa H Kimura S Kuroda J Sato K Nogawa M Yuasa T Yokota A Hodohara K Fujiyama Y Maekawa T The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529 Leuk Res 2005 29 4 451-457 10.1016/ j.leukres.2004.10.004 15725480
20. Yuasa T Nogawa M Kimura S Yokota A Sato K Segawa H Kuroda J Maekawa T A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo Clin Cancer Res 2005 11 2 Pt 1 853-859 15701876
21. Horie N Murata H Nishigaki Y Matsui T Segawa H Nogawa M Yuasa T Kimura S Maekawa T Fushiki S Kubo T The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis Cancer Lett 2006 238 1 111-118 10.1016/j.canlet.2005.06.041 16112430
22. Matsumoto S Kimura S Segawa H Kuroda J Yuasa T Sato K Nogawa M Tanaka F Maekawa T Wada H Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines Lung Cancer 2005 47 1 31-39 10.1016/ j.lungcan.2004.06.003 15603852
23. Tannehill-Gregg SH Levine AL Nadella MV Iguchi H Rosol TJ The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice Clin Exp Metastasis 2006 23 1 19-31 10.1007/ s10585-006-9008-z 16715352
24. Herrmann BG Frischauf AM Isolation of genomic DNA Methods Enzymol 1987 152 180-183 3657568
25. Katz ME McCormick F Signal transduction from multiple Ras effectors Curr Opin Genet Dev 1997 7 1 75-79 10.1016/S0959-437X(97)80112-8 9024640
26. Bergstrom JD Bostedor RG Masarachia PJ Reszka AA Rodan G Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase Arch Biochem Biophys 2000 373 1 231-241 10.1006/abbi.1999.1502 10620343
27. van Beek E Pieterman E Cohen L Lowik C Papapoulos S Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo Biochem Biophys Res Commun 1999 255 2 491-494 10.1006/bbrc.1999.0224 10049736
28. Neri A Knowles DM Greco A McCormick F Dalla-Favera R Analysis of RAS oncogene mutations in human lymphoid malignancies Proc Natl Acad Sci U S A 1988 85 23 9268-9272 282720 3057505 10.1073/pnas.85.23.9268
29. Dunford JE Thompson K Coxon FP Luckman SP Hahn FM Poulter CD Ebetino FH Rogers MJ Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates J Pharmacol Exp Ther 2001 296 2 235-242 11160603
30. Shintani S Li C Mihara M Yano J Terakado N Nakashiro K Hamakawa H Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines Oral Oncol 2004 40 1 43-51 10.1016/S1368-8375(03)00131-3 14662414
31. Di Gennaro E Barbarino M Bruzzese F De Lorenzo S Caraglia M Abbruzzese A Avallone A Comella P Caponigro F Pepe S Budillon A Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells J Cell Physiol 2003 195 1 139-150 10.1002/jcp.10239 12599217
32. Sun J Blaskovich MA Knowles D Qian Y Ohkanda J Bailey RD Hamilton AD Sebti SM Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine Cancer Res 1999 59 19 4919-4926 10519405